相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome
Felix Beuschlein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome
Yanan Cao et al.
SCIENCE (2014)
Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma
Joshua N. Honeyman et al.
SCIENCE (2014)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
Phase II trial of temsirolimus in patients with metastatic breast cancer
Gini F. Fleming et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells
Anna-Maria Jegg et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers
Bhuvanesh Dave et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Y. Kataoka et al.
ANNALS OF ONCOLOGY (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
K. L. Blackwell et al.
ANNALS OF ONCOLOGY (2009)
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
F. Vegran et al.
BRITISH JOURNAL OF CANCER (2009)
Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Long Gu et al.
CLINICAL CANCER RESEARCH (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
BAD: undertaker by night, candyman by day
N. N. Danial
ONCOGENE (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
Rita Nahta et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
System for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions
T. S. Wehrman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase
S Taurin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase stabilizes β-catenin through inhibition of its ubiquitination
S Hino et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Consequences of lysine 72 mutation on the phosphorylation and activation state of cAMP-dependent kinase
GH Iyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
WL Xia et al.
ONCOGENE (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Regulation of cellular response to oncogenic and oxidative stress by Seladin-1
CW Wu et al.
NATURE (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel et al.
EUROPEAN JOURNAL OF CANCER (2001)
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
XJ Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155
JM Lizcano et al.
BIOCHEMICAL JOURNAL (2000)
分享论文
